During the American Association of Colleges of Pharmacy (AACP) Annual Meeting in Kissimmee, Fla. in mid-July, Jill Fitzgerald, PharmD, who is Drug Topics CPE accreditor, was sworn in as chair-elect to the AACP Continuing Professional Education Section.
During the American Association of Colleges of Pharmacy (AACP) Annual Meeting in Kissimmee, Fla. in mid-July, Jill Fitzgerald, PharmD, who is Drug Topics CPE accreditor, was sworn in as chair-elect to the AACP Continuing Professional Education Section. She is director of Pharmacy Professional Development, and assistant clinical professor at the University of Connecticut School of Pharmacy, Storrs, Conn.
Beginning her 3-year term, Dr. Fitzgerald is responsible for the development of programming for next year’s annual meeting as it relates to the Continuing Professional Education section. In 2013, she assumes the role of chair, working to implement their strategic goals toward the advancement and practice of Continuing Professional Development. She then will continue in the leadership of the Section as immediate past-chair for her final year.
Dr. Fitzgerald and her office are the accredited provider for continuing education activities for Drug Topics. Together, Drug Topics in partnership with the University of Connecticut School of Pharmacy, will be offering a new opportunity for earning up to 23 CPE credits with the new "Medication Therapy Management CPE Series," starting in September 2012. Click here for more information.
To participate in the current free Drug Topics CPE activities, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
Examining Impact of COVID-19 Diagnosis Timing on AF Progression | AHA 2024
November 21st 2024“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.